Merck: FDA approves expansion of Keytruda label

(CercleFinance.com) - The US Food and Drug Administration has approved expanded use of Keytruda, making Merck's immunotherapy an option for more patients with non-small cell lung cancer.


The expanded label will now include patients for whom combination therapy may not be appropriate, the biopharmaceuticals company said on Thursday.

Merck said the expanded label includes monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 with no EGFR or ALK genomic tumor aberrations.

Copyright (c) 2019 CercleFinance.com. All rights reserved.